Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Neoplasms, Plasma Cell 1Multiple Myeloma 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia 1Breast Neoplasms 1

Interventions

Melphalan 5Dexamethasone 5Prednisone 4Peripheral Blood Stem Cell Transplantation 3Doxorubicin 3Vincristine 2Thalidomide 2Lenalidomide 2Filgrastim 2Cyclophosphamide 2valspodar 1sargramostim 1fludarabine phosphate 1Vancomycin 1Tazobactam 1Reverse Transcriptase Polymerase Chain Reaction 1Radiotherapy 1Platelet Aggregation 1Piperacillin, Tazobactam Drug Combination 1Piperacillin 1Moxifloxacin 1Morphine 1Methotrexate 1Interferon-alpha 1In Situ Hybridization, Fluorescence 1Immunoenzyme Techniques 1Gene Expression Profiling 1Fenretinide 1Etoposide 1Dextromethorphan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Neoplasms, Plasma Cell × valspodar × Clear all
NCT00002878 2023-06-15

Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Eastern Cooperative Oncology Group

Phase 3 Completed
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡